Sepsis is a major cause of morbidity and mortality in the neonatal period , inspite of extensive use of antimicrobial therapy . Sepsis related morbidity and mortality rates are high among preterm infants , especially in the smallest neonates. The increased risk of severe neonatal infections in the extremely preterm infant is thought to be attributable to immature defense mechanisms in combination with the use of invasive treatment techniques . Intravenous immune globulin(IVIG) ,in combination with antibiotic therapy in sepsis ,has been reported to decrease the morbidity and mortality in neonates, by providing immediate high levels of specific antibody that maybe of therapeutic benefit.This study concludes that there is insufficient evidence for routine use of IVIG as an adjunct to standard therapies in neonatal sepsis as there was no significant reduction of morbidity and mortality in the study population following its administration.